Ingelheim, Germany (ots/PRNewswire) – Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], for its efficacy [...]
Tag Archive > Tumours
Encouraging First Data on New Targeted Treatment for Patients With Melanoma – the Deadliest Form of Skin Cancer
Basel, Switzerland (ots/PRNewswire) – – PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic – For Non-US Media Only Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients with advanced melanoma whose cancer harbours [...]
